Treatment of Nasal Airway Obstruction Using the Aerin Medical Device

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02914236
Recruitment Status : Completed
First Posted : September 26, 2016
Results First Posted : March 6, 2018
Last Update Posted : March 6, 2018
Information provided by (Responsible Party):
Aerin Medical

Brief Summary:
Evaluation of the Aerin Medical Device used for the treatment of nasal obstruction.

Condition or disease Intervention/treatment Phase
Nasal Obstruction Device: Vivaer Stylus Not Applicable

Detailed Description:
This is a non-significant risk, prospective, multi-center, non-randomized study to evaluate the safety and efficacy of the Aerin Medical device (Vivaer Stylus) when used to deliver radiofrequency (RF) energy to the nasal valve area to improve symptoms in those diagnosed with nasal airway obstruction.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Center Non-Randomized Study to Evaluate Treatment of Nasal Airway Obstruction Using the Aerin Medical Device
Actual Study Start Date : September 27, 2016
Actual Primary Completion Date : July 21, 2017
Actual Study Completion Date : August 18, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Choking

Arm Intervention/treatment
Experimental: Vivaer Stylus
Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
Device: Vivaer Stylus
Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
Other Name: Aerin Medical Device

Primary Outcome Measures :
  1. Improvement in NOSE Score [ Time Frame: Baseline, 26 weeks ]

    Mean change in Nasal Obstruction Symptom Evaluation (NOSE) score from baseline to 26 weeks post-study procedure. Improvement (baseline score - 26-week score) is signified by a positive value.

    The Nasal Obstruction Symptom Evaluation (NOSE) scale is a validated disease-specific health status outcomes instrument, used to assess severity of nasal obstruction symptoms. Score ranges from 0 to 100. Higher scores indicate increased symptoms/symptom severity.

Secondary Outcome Measures :
  1. NOSE Responder Rate [ Time Frame: Baseline, 26 weeks ]
    Percent subjects who are responders to therapy; responder is defined as a treated subject who experiences at least a 15-point improvement in NOSE score from baseline to 26 weeks post treatment.

  2. Percentage of Participants With Treatment-Related Adverse Events (Safety) [ Time Frame: Baseline through 26 weeks ]
    Characterization of the type and frequency of treatment-related adverse events reported during or following the study procedure, throughout the follow-up period.

Other Outcome Measures:
  1. Subject-reported Pain Related to the Study Procedure, as Reported on 100mm Visual Analog Scale [ Time Frame: Immediately after study procedure, 4-weeks ]

    Procedure-related pain as reported by the subject using a 100mm Visual Analog Scale (VAS), immediately post-procedure and at the 4-week follow-up visit. Higher scores indicate more severe pain.

    The Pain VAS is presented to the subject as a 100mm line anchored on each end by verbal descriptors: 0 = no pain and 100 = worse pain imaginable. The distance between 0 and the vertical mark made by the subject is measured and the result is expressed in millimeters.

  2. Subject Satisfaction [ Time Frame: 26 weeks ]
    Study-specific survey to assess patient satisfaction with the discomfort of the procedure and recovery period, as well as their perceived results. The survey included 5 questions related to tolerability of the procedure, ease of recovery, change in breathing, satisfaction with treatment, and willingness to recommend treatment. Each question was scored on a 10-point scale, with 1 indicating the most negative response to the question (e.g., "very bad", "much worse", or "very dissatisfied") and 10 indicating the most favorable rating (e.g., "hardly noticeable", "much better", or "very satisfied"). Each question was individually scored and reported.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   22 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Seeking treatment for nasal obstruction and willing to undergo an office-based procedure
  • Nasal Obstruction Symptom Evaluation (NOSE) score of ≥ 60 at Baseline
  • Nasal valve is a primary or significant contributor to the subject's nasal obstruction as determined by the study investigator (based on clinical presentation, physical examination, nasal endoscopy, etc.) and the subject has a positive response to any of the following temporary measures (based on patient history or office exam):
  • Use of external nasal dilator strips (e.g., Breathe Right Strips)
  • Q-Tip test (manual intranasal lateralization)
  • Use of nasal stents
  • Cottle Maneuver (manual lateral retraction of the cheek)

Exclusion Criteria:

  • Prior surgical treatment of the nasal valve
  • Rhinoplasty, septoplasty, inferior turbinate reduction or other surgical nasal procedures within the past twelve (12) months
  • Chronic sinusitis, recurrent sinusitis, or allergies leading to nasal obstruction
  • Septal deviation, turbinate hypertrophy, polyps, or ptotic nose tip believed to be a significant contributor to the subject's nasal obstruction symptoms
  • Known or suspected allergies or contraindications for any general or local anesthetic agents and / or any antibiotic medications
  • Known or suspected to be pregnant, or is lactating
  • Other medical conditions which in the opinion of the investigator could predispose the subject to poor wound healing or increased surgical risk

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02914236

United States, California
Central California Clinical Research
Fresno, California, United States, 93720
United States, Colorado
Colorado ENT and Allergy
Colorado Springs, Colorado, United States, 80909
United States, New Jersey
ENT and Allergy Associates, LLP
Oradell, New Jersey, United States, 07649
United States, New York
ENT and Allergy Associates, LLP
Bayside, New York, United States, 11360
ENT and Allergy Associates, LLP
New Hyde Park, New York, United States, 11042
ENT and Allergy Associates, LLP
New York, New York, United States, 10017
ENT and Allergy Associates, LLP
Staten Island, New York, United States, 10314
United States, North Carolina
Piedmont Ear, Nose and Throat Associates
Winston-Salem, North Carolina, United States, 27103
United States, Texas
Ear, Nose and Throat Associates of Texas
McKinney, Texas, United States, 75070
Sponsors and Collaborators
Aerin Medical
Study Director: Scott Wolf, MD Aerin Medical
Principal Investigator: Ofer Jacobowitz, MD, PhD Mount Sinai Hospital, New York, NY
  Study Documents (Full-Text)

Documents provided by Aerin Medical:

Responsible Party: Aerin Medical Identifier: NCT02914236     History of Changes
Other Study ID Numbers: TP258
First Posted: September 26, 2016    Key Record Dates
Results First Posted: March 6, 2018
Last Update Posted: March 6, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Aerin Medical:
Nasal valve
Nasal airway obstruction

Additional relevant MeSH terms:
Airway Obstruction
Nasal Obstruction
Respiratory Insufficiency
Respiration Disorders
Respiratory Tract Diseases
Nose Diseases
Otorhinolaryngologic Diseases